drugset / Trial / NCT00077168

Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole

NCT00077168

Phase 2 Unknown 2000 enrolled Institute of Cancer Research, United Kingdom
RandomizedTreatment

Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether radiation therapy after surgery is effective in preventing a recurrence of ductal carcinoma in situ. PURPOSE: This randomized phase II trial is studying adjuvant radiation therapy to see how well it works compared to observation after surgery in treating women with estrogen receptor positive or progesterone receptor positive ductal carcinoma in situ and are also receiving either tamoxifen or anastrozole.

Timeline

Start
2004-04
Primary completion
2017-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Background Anastrozole Other / unclassified
Background Tamoxifen Small molecule

Indications